Federal Sunshine Act Defense Attorneys - Oberheiden, P.C.
WSJ logo
Forbes logo
Fox News logo
Bloomberg logo
Los Angeles Times logo
Washington Post logo
The Epoch Times logo
CNN logo
Telemundo logo
New York Times
NY Post logo
NBC logo
Daily Beast logo
USA Today logo
Miami Herald logo
CNBC logo
Dallas News logo
Quick Practice Area Locator

What Are the Reporting Requirements under the Sunshine Act?

sunshine act reporting requirements

The Sunshine Act requires applicable manufacturers to report payments or other transfers of value to physicians or teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members.  See 42 U.S.C. § 1320a-7h.

Important Terminology

The key to understanding the requirements under the Sunshine Act is to understand the complex definitions that may trigger reporting obligations.  In the absence of court guidance, much interpretation of the federal Sunshine Act remains open to interpretation.

1. Who is an Applicable Manufacturer?

The Sunshine Act applies to “applicable manufacturers,” which the law defines in two ways: first, as any entity which is engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device, biological, or medical supply, and which is operating in the United States, or in a territory, possession, or commonwealth of the United States, including distributors or wholesalers that hold title to a covered product, and second, any entity under common ownership with an entity described above, which provides assistance or support to such entity with respect to the production, preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered drug, device, biological, or medical supply, and which is operating in the United States, or in a territory, possession, or commonwealth of the United States.  See 42 U.S.C. § 1320a-7h (e)(2),(e)(9).

2. What Are Covered Devices?

A “covered device” is any device or medical supply for which payment is available under Medicare, Medicaid, or Children’s Health Insurance Program (“CHIP”); and requires FDA premarket approval or premarket notification.  See 42 U.S.C. § 1320a-7h(e)(4); 78 Fed. Reg. 9465.

Put our highly experienced team on your side

Dr. Nick Oberheiden
Dr. Nick Oberheiden



Lynette S. Byrd
Lynette S. Byrd

Former DOJ Trial Attorney


Brian J. Kuester
Brian J. Kuester

Former U.S. Attorney

Amanda Marshall
Amanda Marshall

Former U.S. Attorney

Local Counsel

Joe Brown
Joe Brown

Former U.S. Attorney

Local Counsel

John W. Sellers
John W. Sellers

Former Senior DOJ Trial Attorney

Linda Julin McNamara
Linda Julin McNamara

Federal Appeals Attorney

Aaron L. Wiley
Aaron L. Wiley

Former DOJ attorney

Local Counsel

Roger Bach
Roger Bach

Former Special Agent (DOJ)

Chris Quick
Chris J. Quick

Former Special Agent (FBI & IRS-CI)

Michael S. Koslow
Michael S. Koslow

Former Supervisory Special Agent (DOD-OIG)

Ray Yuen
Ray Yuen

Former Supervisory Special Agent (FBI)

3. What Defines Common Ownership?

In this context, common ownership is defined as circumstances where the same individual(s) or entity(ies) owns five percent or more of total ownership in two or more entities.  See 78 Fed. Reg. 9463. The caveat with that definition is that entities that are under common ownership are only subject to reporting requirements when they provide “assistance or support” for the manufacturing activities.  “Assistance or support” is defined as being necessary or integral to the production, preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered product. To constitute “assistance and support” it is necessary that the activities directly and not just tangentially impact the manufacturing process. See 78 Fed. Reg. 9463-64.

4. Excluded Indirect Payments

Payments made indirectly to a covered recipient through a third party when the applicable manufacturer is unaware of the identity of the physician are excluded from the Sunshine Act reporting requirements. See 42 U.S.C. § 1320a-7h(e)(10), 78 Fed.Reg. 9489. The applicable manufacturer must be unaware of the identity of the physician during the reporting year and the second quarter of the subsequent year following the transfer of the payment from the third party to the physician.  See 78 Fed.Reg. 9491.

Limitation to Federal Programs?

Does the Sunshine Act only apply to federally funded services and items? As seen, in order for the Sunshine Act to apply, an entity must qualify as an “applicable manufacturer,” meaning it operates in “covered devices.”  Application of the Sunshine Act depends on whether payment is “available” under one of the government programs, such as Medicare, Medicaid, or CHIP.

While the Sunshine Act itself provides very little guidance on the interpretation of the term “available,” reference to other prominent federal healthcare laws may assist in determining the appropriate interpretation.  The Ethics in Patient Referrals Act (commonly referred to as “Stark”), for example, applies to individuals and entities that received or qualify to receive federal funds. See 42 U.S.C. § 1395nn(a)(1).  And the federal Anti-Kickback Statute uses similar terminology (“any item or service for which payment may be made in whole or in part under a Federal healthcare program”) and only applies to services and items that were provided to patients under a federal healthcare program.  See 42 U.S.C. § 1320a-7b(b). At least in the context of the federal Anti-Kickback Statute, the Office of Inspector General has clarified in OIG Advisory Opinion No. 11-085 (June 14, 2011) that even though the federal Anti-Kickback Statute is meant to apply only to federally funded programs, enforcement under the federal Anti-Kickback Statute of arrangements that do not include federally funded patients is nonetheless justified if and when the arrangement attempts to circumvent the federal Anti-Kickback Statute by way of bundling non-federal and federal patients or otherwise disguising the true nature of the arrangement.

For purposes of the Sunshine Act, these parallel impressions from Stark Law and Anti-Kickback Statute may impact future law enforcement interpretations and may, under certain circumstances, subject non-federally funded program entities to the scope of the Sunshine Act.

Free Consultation

As seen, the Sunshine Act is a complex and yet untested law that may subject entities and physicians to rigorous reporting requirements and public disclosures of financial information. The experienced attorneys of Oberheiden, P.C. are familiar with the Sunshine Act and have advised entities, business owners, physicians, and other healthcare professionals on their respective reporting obligations. If you have any questions, please contact us for a free and confidential consultation.

Oberheiden, P.C.
Litigation – Compliance – Defense
This information has been prepared for informational purposes only and does not constitute legal advice. This information may constitute attorney advertising in some jurisdictions. Reading of this information does not create an attorney-client relationship. Prior results do not guarantee similar future outcomes. Oberheiden, P.C. is a Texas PC with headquarters in Dallas. Mr. Oberheiden limits his practice to federal law.

Why Clients Trust Oberheiden P.C.

  • 95% Success Rate
  • 2,000+ Cases Won
  • Available Nights & Weekends
  • Experienced Trial Attorneys
  • Former Department of Justice Trial Attorneys
  • Former Federal Prosecutors, U.S. Attorney’s Office
  • Former Agents from FBI, OIG, DEA
  • Cases Handled in 48 States
Email Us 888-680-1745